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Abstract: We report the case of a 41-year-old female with bilateral orbital Rosai-Dorfman 
disease (RDD) and the result of corticosteroid therapy. The patient developed a swollen mass 
of bilateral upper and lower eye-lid over a six-month period. Diagnosis was based on the char-
acteristic histopathologic features. She was treated with oral corticosteroids 60 mg/per day for 
ten days and the dose of corticostreoid was tapered every week. She is currently being treated 
with 10 mg/per day for 4 months. In general, the prognosis is good, with experiencing remission 
following a course of oral corticosteroids. There is no evidence that corticosteroids are beneﬁ  cial 
in the treatment of RDD in the literature, but data regarding such treatment are sparse. A more 
formalized surveillance of these cases would help to deﬁ  ne more clearly the natural history of 
the disease and the effects of various treatment modalities.
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Introduction
Rosai-Dorfman disease (RDD) is an uncommon reactive histiocytic proliferative disor-
der of unknown cause (Wong et al 1989). The ﬁ  rst case of RDD was reported in 1965, 
but its importance was not recognized until Rosai and Dorfman described four cases of 
what they called “sinus histiocytosis with massive lymphadenopathy” in 1969 (Rosai and 
Dorfman 1969). This is a nonneoplastic disease of unknown etiology observed mainly 
in adolescents with markedly enlarged cervical or other lymph nodes (Wong et al 1989). 
RDD generally presents third to ﬁ  fth decades of life (although presentation in children 
and the elderly  has also been reported) with cervical lymphadenopathy often preceded 
by symptoms suggestive of a viral infection (Foucar et al 1979). The majority of patients 
have elevation of the erythrocyte sedimentation rate (ESR) and a polyclonal increase in 
globulins (Yip et al 2002). Nevertheless, there are numerous published cases without 
lymphadenopathy. So-called extranodal disease occurs in some 25% of cases and may arise 
in the orbit, nasopharynx, respiratory pathways, gastrointestinal tract, endocrine glands 
(particularly the thyroid), bone, skin, and nervous system. Ten percent of patients have 
orbital involvement, but only one-third of those with orbital involvement have bilateral 
disease. The disease is usually chronic and refractory to various treatment modalities.
There are previously reported cases of ocular RDD without clinically detectable 
systemic involvement, however we report the clinical and histopathological features 
of a case of RDD with bilateral orbital and unusual articular, abdominal involvement, 
and the successfull result of systemic streoid treatment.
Case report
The patient was a 41-year old woman, who developed a swollen mass of bilateral 
upper and lower eye-lid over a six-month period (Figure 1a). Examination revealed Clinical Ophthalmology 2008:2(2) 480
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a large, noninﬂ  amed, nontender mass in bilateral lower and 
upper eyelid. Anterior segment examination and fundos-
copy were essentially normal. There was no preauricular or 
cervical lymph node enlargement. On systemic evaluation, 
there were severe congenital deformations both on hands 
and legs which couldn’t be related to any rheumatological 
or other systemic disease. She also had poor hearing since 
early childhood which diagnosed as bilateral sensorio-neural 
hearing loss. Also in her history, 17 years ago, there was an 
abdominal surgery with poor medical records.
Coronal images obtained by magnetic resonance imaging 
showed a homogeneous mass involving bilateral infratem-
poral fossa, nasale cavity, lacrimal gland, and buccal and 
perimandibular interface in the left side (Figure 2). Surgi-
cal excision biopsy of the mass was performed under local 
anesthesia. Histopathological examination was consistent 
with a diagnosis of RDD. The inﬁ  ltrate is composed of his-
tiocytes with a characteristic immunohistochemical proﬁ  le 
(S100-positive) together with small lymphocytes and plasma 
cells.
She was treated with oral corticosteroids 60 mg/per day 
for ten days and the dose of corticostreoid was tapered every 
week. She is currently being treated with 10 mg/per day for 
6 months.
In general, the prognosis is good, with the remission of 
orbital masses following a course of oral corticosteroids at 
one month (Figure 3).
Conclusion
Ocular involvement in RDD is rare (%10) (Foucar et al 
1979). The diagnosis of RDD was based on histopathological 
examination with very clear and typical histopathological 
features of the disease described above.
However, there was no previous report and no relation-
ship, as far as we know, between the mass lesions of RDD 
and either the deformities on extremities or the hearing loss 
or history of the abdominal surgery. A previous report was 
mentioned about a patient of RDD with bilateral orbital 
masses having subcutaneous masses in the lower abdominal 
wall, backache and lower extremity weakness. They reported 
Figure 1 Pre-treatment photography of the patient shows a swollen mass of 
bilateral upper and lower eye-lid over a six-month period.
Figure 2 Post-treatment photography shows an partial remission of orbital masses 
following a course of oral corticosteroids at one month.
Figure 3 Coronal images obtained by magnetic resonance imaging showed a 
homogeneous mass involving bilateral infratemporal fossa, nasale cavity, lacrimal 
gland, and buccal and perimandibular interface in the left side.Clinical Ophthalmology 2008:2(2) 481
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that the pathologic specimens from the abdominal masses, 
paravertebral tissues, and eyelid tissues were reviewed, and 
the ﬁ  nal diagnosis was RDD (Yip et al 2002). So, we don’t 
know if these separate ﬁ  ndings in our cases were coincidental 
or any unknown feature of the disease. Our systemic work-up 
results were negatively for RDD.
The data available do not allow for the establishment 
of deﬁ  nitive treatment protocols for the ocular complica-
tions of RDD, although many therapeutic options, such as 
surgery, radiotherapy, oral corticosteroids, and antibiotics, 
have been described (de Silva and Joshi 2005). Reports of 
complete remission are few and most have occurred with 
the use of combinations of corticosteroids, vinca alkaloids, 
and alkylating agents (Komp 1990). Treatment is indicated 
if there is functional impairment of one or more organ 
systems (Mohadjer et al 2006). We used oral corticoste-
roid alone such a patient of RDD with eyelid masses. She 
was treated with oral corticosteroids 60 mg/per day for ten 
days and the dose of corticostreoid was tapered at 10 mg 
every week. She is currently being treated with 10 mg/per 
day for 6 months. In general, the prognosis is good, with 
experiencing remission of orbital masses following a short 
course of oral corticosteroids. A positive response to the 
treatment was seen in the ﬁ  rst week. The stabilization was 
achieved in one month.
RDD is a rare condition and should be considered in the 
differential diagnosis of orbital or eyelid soft tissue enlarge-
ment. Medical management with corticosteroid should be 
considered, as RDD was diagnosed. Long-term follow-up is 
required as potentially vision-threatening complication and 
recurrence may occur.
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